2022
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 2022, 27: 2273-2281. PMID: 35165397, PMCID: PMC9133063, DOI: 10.1038/s41380-022-01465-2.Peer-Reviewed Original ResearchConceptsKetamine's therapeutic effectsMajor depressive disorderTherapeutic effectPositron emission tomographyPosttraumatic stress disorderHealthy controlsSynaptic connectionsSynaptic vesicle protein 2APost-synaptic mechanismsEffects of ketamineDiscovery of ketamineNon-human primatesAntidepressant effectsDepressive disorderSingle administrationSynaptic densityPsychiatric disordersDepression severityKetamineEmission tomographyTerminal densityLiving brainStress disorderRobust reductionDissociative symptoms
2009
A critical review of human endotoxin administration as an experimental paradigm of depression
DellaGioia N, Hannestad J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neuroscience & Biobehavioral Reviews 2009, 34: 130-143. PMID: 19666048, PMCID: PMC2795398, DOI: 10.1016/j.neubiorev.2009.07.014.Peer-Reviewed Original ResearchConceptsImmune system activationEndotoxin administrationSystem activationImmune stimuliDepressive symptomsInnate immune system activationElicit depressive symptomsInterferon-alpha treatmentCommon final pathwayPotential molecular pathwaysImmunologic abnormalitiesImmune depressionVaccine administrationInflammatory cytokinesDepression paradigmDepressed patientsFinal pathwaySymptomsDepression researchAdministrationDepressionMolecular pathwaysBehavioral changesActivationRodents